Valuation: Synovics Pharmaceuticals, Inc.

Market Cap 16.41L 14.48L 13.7L 12.42L 23.29L 16Cr 23.52L 1.64Cr 63.33L 8.04Cr 61.6L 60.26L 26Cr P/E 2007
-0.73x
P/E 2008 -2.06x
Enterprise Value 81.29L 71.74L 67.87L 61.56L 1.15Cr 78Cr 1.17Cr 8.14Cr 3.14Cr 40Cr 3.05Cr 2.99Cr 128.18Cr EV / Sales 2007
1.81x
EV / Sales 2008 0.6x
Free-Float
95.75%
Yield 2007 *
-
Yield 2008 -
1 day-50.00%
6 months+9,900.00%
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-.--%-.--%-.--% 3.65T
+0.02%+1.33%+63.20%+120.74% 1,05600Cr
-1.81%-0.67%+47.22%+71.67% 66TCr
-1.00%-0.47%+18.29%+77.09% 47TCr
-1.72%-4.06%+36.39%+39.47% 34TCr
-0.40%+3.83%+22.08%+28.82% 28TCr
-0.51%-1.93%+12.09%+11.94% 26TCr
+1.14%+3.03%+54.27%+57.26% 23TCr
-0.21%-0.62%+34.72%+102.46% 19TCr
-0.24%-2.76%-28.41%-60.92% 17TCr
Average -5.47%+0.87%+25.98%+44.85% 36.43TCr
Weighted average by Cap. -0.62%+1.04%+38.97%+70.62%

Financials

2007 2008
Net sales 2.35Cr 2.07Cr 1.96Cr 1.78Cr 3.33Cr 225.17Cr 3.36Cr 24Cr 9.06Cr 114.98Cr 8.81Cr 8.62Cr 370.02Cr 2.6Cr 2.29Cr 2.17Cr 1.97Cr 3.69Cr 249.1Cr 3.72Cr 26Cr 10Cr 127.2Cr 9.75Cr 9.54Cr 409.34Cr
Net income -2.09Cr -1.84Cr -1.74Cr -1.58Cr -2.96Cr -200.14Cr -2.99Cr -21Cr -8.05Cr -102.2Cr -7.83Cr -7.66Cr -328.89Cr -40.06L -35.35L -33.45L -30.33L -56.87L -38Cr -57.43L -4.01Cr -1.55Cr -20Cr -1.5Cr -1.47Cr -63Cr
Net Debt 1.88Cr 1.66Cr 1.57Cr 1.42Cr 2.67Cr 180.3Cr 2.69Cr 19Cr 7.25Cr 92Cr 7.06Cr 6.9Cr 296.29Cr 64.88L 57.26L 54.18L 49.13L 92.11L 62Cr 93.02L 6.5Cr 2.5Cr 32Cr 2.44Cr 2.38Cr 102.31Cr
Logo Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Employees
155
  1. Stock Market
  2. Stocks
  3. SYVC Stock